



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/735,514
				Filing Date	December 11, 2003
				First Named Inventor	Daniel A. Moros
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	03939/100M269-US1


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
ESO	1	US-6,281,207	08-28-2001	Richter et al.	entire document
ESO	2	US-6,093,820	07-25-2000	Gutman et al.	entire document
ESO	3	US-5,985,856	11-16-1999	Stella et al.	entire document
ESO	4	US-5,456,851	10-10-1995	Liu et al.	entire document
ESO	5	US-4,628,056	12-09-1986	Levitt et al.	entire document
ESO	6	US-4,260,769	04-07-1981	Stella et al.	entire document
ESO	7	US-3,679,683	07-25-1972	Gorbaty	entire document

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
ESO	8	WO 03/063872 A1 ✓	08-07-2003	Taro Pharmaceutical Industries Ltd.	entire document	
ESO	9	WO 01/79185 A1 ✓	10-25-2001	Kenneth Curry	entire document	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
ESO	10	Rev. Neurol, 2001, 32 (6): 520-524; I. Balas et al. "Talamotomia estereotaxica de la enfermedad de Parkinson y otros tipos de temblor. Experiencias de la actividad multiunitaria <i>burst</i> en el talamo basada en semimicroelectrodos". (English Abstract)			
ESO	11	Clinician, May 2001, Vol. 19, No. 2, pp. 1-15, "Essential Tremor: A Practical Guide to Evaluation, Diagnosis, and Treatment".			
ESO	12	Movement Disorders, Vol. 16, No. 3, 2001 pp 464-468, William C. Koller, et al. "Long Term Safety and Efficacy of Unilateral Deep Brain Stimulation of the Thalamus in Essential Tremor".			
ESO	13	The New England Journal of Medicine, Vol. 345, No. 12, Sept. 2001 pp 887-891, Elan D. Louis, "Essential Tremor".			
ESO	14	Neurology, June 2000, Vol. 54, Suppl 4, S8-S13, Leslie J. Findley, "Epidemiology and Genetics of Essential Tremor".			
ESO	15	Neurology, June 2000 Vol. 54, Suppl. 4, S30-S38, William C. Koller et al., "Pharmacologic Treatment of Essential Tremor"			
ESO	16	Archives of Neurology, April 1999, Vol. 56, No. 4: 475-480, Alexandre Gironell, et al., "A Randomized Placebo-Controlled Comparative Trial of Gabapentin and Propranolol in Essential Tremor".			

Signature	/Eric Olson/	Date Considered	08/09/2006
-----------	--------------	-----------------	------------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/735,514
				Filing Date	December 11, 2003
				First Named Inventor	Daniel A. Moros
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	03939/100M269-US1

ESO	17	The New England Journal of Medicine, Vol. 339, No. 16, Oct. 1998, pp. 1130-1143, Anthony E. Lang, et al. "Parkinson's Disease", Second of Two Parts.	
ESO	18	Movement Disorders, Vol. 13, Suppl 3., pp 90-100, 1998, Paul G. Wasielewski, et al. "Pharmacologic Treatment of Tremor".	
ESO	19	Mayo Clinic Proceedings, Vol. 66, No. 10, Oct. 1991, pp. 991-997, Manfred D. Muentert, et al. "Treatment of Essential Tremor With Methazolamide".	
ESO	20	Parkinson's Disease and Movement Disorders, Urban & Schwarzenberg, Inc., 1988, 17: 225-234, Stanley Fahn, et al. "Clinical Rating Scale for Tremor"	
ESO	21	Movement Disorders 2, 1987, (22) 438-458, Leslie J. Findley, "The Pharmacology of Essential Tremor".	
ESO	22	Modern Pharmacology, 2nd Ed., 1986, Ch. 4, pp. 41-64, Theodore E. Gram "Metabolism of Drugs".	
ESO	23	Journal of Neurology, Neurosurgery, and Psychiatry, 1985; 48, No. 9, 911-915, Leslie J. Findley et al., "Primidone in Essential Tremor of the Hands and Head: A Double Blind Controlled Clinical Study".	
ESO	24	C.D. Marsden, Origins of Normal and Pathological Tremor in Movement Disorders : Tremor. Eds. L.J. Findley and R. Capildeo, New York. Oxford University Press, 1984, pp 37-84 "Origins of Normal and Pathological Tremor".	
ESO	25	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed. Ch. 17, 361-396, William R. Hobbs et al., "Hypnotics and Sedatives; Ethanol".	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Signature	/Eric Olson/	Date Considered	08/09/2006
-----------	--------------	-----------------	------------



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/735,514
				Filing Date	December 11, 2003
				First Named Inventor	Daniel A. Moros
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	03939/100M269-US1
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
ESO	AA	US-3,930,006-B1	12-30-1975	Wiggins et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
ESO	BA	WO-01/39779-A1	06-07-2001	UCB, S.A.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
ESO	CA	Sturfelt, G. et al.: "Acute Effects of Barbiturates in Parkinson's Disease," ACTA MEDICA SCANDINAVICA, ALMQVIST & WIKSELL PERIODICAL CO., Stockholm, SE, vo. 201, no. 1/2, 1977, pages 75-76, XP000937405.			
ESO	CB	Hamann, M. et al.: "Effects of striatal injections of GABAA receptor agonists and antagonists in a genetic animal model of paroxysmal dystonia," EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 443, no. 1-3, 17 May 2002, pages 59-70, XP002284223.			
ESO	CC	Bashir, K. et al.: "Clozapine for the control of hemiballismus," CLINICAL NEUROPHARMACOLOGY, vol. 17, no. 5, 1994, pages 477-480, XP009032005.			
ESO	CD	Sasso, E. et al.: "Double-Blind Comparison of Primidone and Phenobarbital in Essential Tremor," NEUROLOGY, vol. 38, no. 5, 1988, pages 808-810, XP009032012.			
ESO	CE	Ondo, W. et al.: "Essential tremor. Treatment Options," CNS DRUGS 1996 NEW ZEALAND, vol. 6, no. 3, 1996, pages 178-191, XP009032012.			
ESO	CF	International Search Report.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Eric Olson/	Date Considered	08/09/2006
-----------------------	--------------	--------------------	------------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/735,514
				Filing Date	December 11, 2003
				First Named Inventor	Daniel A. Moros
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	03939/100M269-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
1 ESO	1	Arch Otolaryngol, Vol. 110, June 1984, pp 394-397, "Spastic Dysphonia and Essential (Voice) Tremor Treated With Primidone", David E. Hartman, et al.		
2. ESO	2	Journal of Neurology, Neurosurgery, and Psychiatry 1985;48:911-915, "Primidone in Essential Tremor of the Hands and Head: A Double Blind Controlled Clinical Study", Leslie J. Findley, et al.		
3. ESO	3	Neurology, 1985; 35:1874-1787, "Phenobarbitone in Essential Tremor", Leslie J. Findley, et al.		
4. ESO	4	Journal of Neurology, Neurosurgery, and Psychiatry 1986;49:64-68, "A Comparison of Primidone, Propranolol, and Placebo in Essential Tremor, Using Quantitative Analysis", W.P. Gorman, et al.		
5. ESO	5	Neurology, 1986; 36:121-124, "Efficacy of Primidone In Essential Tremor", William C. Koller, et al.		
6. ESO	6	Clinical Neuropharmacology Vol. 10, No. 4, 1987, pp. 342-350, "Essential Tremor Variants: Effect of Treatment, William C. Koller, et al.		
7. ESO	7	Acta Neurol Scand., 1987;75:332-340, "Primidone and Propranolol in Essential Tremor: A Study Based on Quantitative Tremor Recording and Plasma Anticonvulsant Levels", P. Dietrichson, et al.		
8. ESO	8	Neurology, 1988, 38:808-810, "Double-Blind Comparison of Primidone and Phenobarbital In Essential Tremor"; Enrico Sasso, et al.		
9 ESO	9	Clinical Neuropharmacology, Vol. 13, No. 3, 1990, pp 210-223, "Basic Mechanism of Action of Drugs Used in the Treatment of Essential Tremor", Xiao-Ming Guan, et al.		
10 ESO	10	Clinical Neuropharmacology, Vol. 13, No. 1, 1990, pp. 67-76, " Primidone in the Long-Term Treatment of Essential Tremor: A Prospective Study with Computerized Quantitative Analysis", Enrico Sasso, et al.		
11 ESO	11	Movement Disorders, Vol. 6, No. 1, 1991, pp. 65-68, "Quantitative Comparison of Barbiturates in Essential Hand and Head Tremor", Enrico Sasso, et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

{W:039 39/100	/Eric Olson/	Date Considered	08/09/2006
------------------	--------------	--------------------	------------